Stay updated with breaking news from John Farley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The respiratory virus is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
This fall, parents and pediatricians will have a new option to protect babies from a lung-attacking virus that is the leading cause of hospitalization in infants under a year old in the United States every year.
(CNN) — This fall, parents and pediatricians will have a new option to protect babies from a lung-attacking virus that is the leading cause of hospitalization in infants under a
Sanofi's RSV antibody shot, nirsevimab, got FDA approval to protect infants on Monday.